Chemoembolization composition comprising anti-angiogenic agents
AssigneeCentre Hospitalier Universitaire Vaudois
InventorsAlban Denys, Pierre Bize, Olivier Jordan, Eric Doelker, Nathalie Boulens
Life of this patent
Estimating the term…
Abstract
The invention relates to chemoembolization compositions for anti-angiogenic agent delivery. The invention further relates to a method of preparing chemoembolization compositions and to the use of chemoembolization compositions in the method for treating solid tumour cancers.
Claims33
A method for treating a solid tumor cancer in a patient comprising administering to said patient a therapeutically effective amount of a chemoembolization composition comprising anti-angiogenic agent and a sugar or poly-ol loaded in anionic drug eluting beads;
- wherein said anionic drug eluting beads comprise a hydrophilic, water-insoluble, biocompatible polymeric material bearing negatively charged groups;
- wherein said antiangiogenic agent is electrostatically bonded to the polymer;
- wherein said anti-angiogenic agent is selected from the group consisting of sunitinib, angiostatin K1-3, arresten, DL-α-difluoromethyl-ornithine, fumagillin, genistein, staurosporine, (±)-thalidomide, tumstatin, axitinib, bortezomib, bosutinib gefitinib, pazopanib, semaxanib, sorafenib, vandetanib, vatalanib, canertinib, dovitinib, dasatinib, erlotinib, imatinib, lapatinib, masutinib, mubitinib, lestaurtinib, pazopanib, tandutinib and vismodegib.
A method for treating a solid tumor cancer in a patient comprising administering to said patient a therapeutically effective amount of a chemoembolization composition comprising anti-angiogenic agent and a sugar or poly-ol loaded in anionic drug eluting beads;
- wherein said anionic drug eluting beads comprise a hydrophilic, water-insoluble, biocompatible polymeric material, bearing negatively charged groups;
- where said antiangiogenic agent is electrostatically bonded to the polymer,
- wherein said anti-angiogenic agent is selected from the group consisting of sunitinib, angiostatin K1-3, arresten, DL-α-difluoromethyl-ornithine, fumagillin, genistein, staurosporine, (±)-thalidomide, tumstatin, axitinib, bortezomib, bosutinib gefitinib, pazopanib, semaxanib, sorafenib, vandetanib, vatalanib, canertinib, dovitinib, dasatinib, erlotinib, imatinib, lapatinib, masutinib, mubitinib, lestaurtinib, pazopanib, tandutinib and vismodegib;
- wherein said anionic drug eluting beads comprise a sugar or poly-ol solution;
- and
- wherein said chemoembolization composition does not comprise precipitated drug.
A method for treating a solid tumor cancer in a patient comprising administering to said patient a therapeutically effective amount of a chemoembolization composition comprising an anti-angiogenic agent and a sugar or poly-ol loaded in anionic drug eluting beads;
- wherein said anionic drug eluting beads comprise a hydrophilic, water-insoluble, biocompatible polymeric material, bearing negatively charged groups;
- wherein said antiangiogenic agent is electrostatically bonded to the polymer;
- wherein said anti-angiogenic agent is selected from the group consisting of sunitinib, angiostatin K1-3, arresten, DL-α-difluoromethyl-ornithine, fumagillin, genistein, staurosporine, (±)-thalidomide, tumstatin, axitinib, bortezomib, bosutinib gefitinib, pazopanib, semaxanib, sorafenib, vandetanib, vatalanib, canertinib, dovitinib, dasatinib, erlotinib, imatinib, lapatinib, masutinib, mubitinib, lestaurtinib, pazopanib, tandutinib and vismodegib;
- wherein said anionic drug eluting beads comprise a sugar or poly-ol solution;
- and
- wherein said anionic drug eluting beads do not comprise precipitated drug.
Dependencies are inferred from the claim text.